Menopur market forecast points to faster growth through 2035

The Menopur fertility drug market is expanding as infertility rates rise, maternal age increases and IVF access widens worldwide. The Business Research Company says North America led the market in 2025, while Asia-Pacific is poised for the fastest growth through 2035.

Why it matters: - Menopur is used in assisted reproductive technology, including IVF, so market growth tracks broader demand for fertility care. - Rising infertility, later childbearing and wider access to fertility services are increasing the need for hormone-based treatment options. - The market outlook matters for fertility clinics, reproductive health providers and drug makers serving a growing patient base.

What happened: - The Business Research Company released a Menopur market report covering market size, trends and a global forecast for 2026-2035. - The report says the market is drawing attention as fertility treatments become more accessible and demographics shift. - The company made a free sample report available here. - The full report is available here.

The details: - Menopur contains human menopausal gonadotropin, or hMG, which includes luteinizing hormone and follicle-stimulating hormone. - The drug is mainly used for women undergoing ART procedures such as IVF. - Menopur works by stimulating the ovaries to develop multiple follicles, which can improve egg retrieval and fertilization chances. - The report identifies rising infertility as a primary market driver. - The report defines infertility as the inability to conceive after one year of regular unprotected intercourse. - Lifestyle changes, environmental pollutants and delayed childbearing are contributing to infertility. - The World Health Organization reported in April 2023 that about 17.5% of adults globally, or roughly one in six people, experience infertility. - Rising healthcare spending is another growth driver. - The UK Office for National Statistics said in May 2024 that nominal healthcare expenditure rose 5.6% between 2022 and 2023, compared with 0.9% growth the year before. - The report links higher spending to greater use of fertility treatments that may reduce repeated assisted reproduction cycles. - Rising maternal age is also supporting demand. - The UK Office for National Statistics said in April 2025 that the average age of women at childbirth in England and Wales was 30.9 years.

Between the lines: - The market forecast reflects a broader shift toward personalized fertility protocols and stronger support for home-based fertility treatment. - The report also points to fertility tourism, expanded fertility clinic networks and improved ovarian stimulation protocols as growth themes. - Demand is being shaped by more than one demographic force at once, which can make fertility treatment markets more durable than single-factor trends. - The report’s emphasis on treatment success rates suggests providers and patients are increasingly focused on outcomes, not just access.

What's next: - The report expects continued growth from personalized fertility care, reproductive health investment and broader ART adoption. - The Business Research Company says key trends will include increased use of hormonal fertility therapies and injectable gonadotropins. - North America held the largest share of the global Menopur market in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics and technology and trend analysis.

The bottom line: - Menopur’s market is set to grow as fertility care becomes more common, more specialized and more globally accessible.